• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aspire Capital to acquire $20m worth of Valeritas stock

September 26, 2017 By Sarah Faulkner

ValeritasValeritas (NSDQ:VLRX) said today that it inked a deal with Aspire Capital Fund to buy $20 million of Valeritas’ common stock.

According to the deal, Aspire Capital is slated to purchase common stock at Valeritas’ request from time to time during a 30-month period at prices based on the market price at the time of each sale.

“This agreement with Aspire provides us access to capital to support our commercial operations and advancing our product pipeline,” president & CEO John Timberlake said in prepared remarks.

“Our relationship with Aspire allows us to strengthen our balance sheet over time without banking commissions or warrants. Controlling the timing and amount of common stock being sold is key, as we can use this facility to opportunistically strengthen our balance sheet over the next thirty months without unnecessary dilution.”

In May, Valeritas reported that a retrospective analysis of 86 diabetic patients who switched from multiple daily insulin injections to the V-Go insulin pump demonstrated a 44% reduction in total daily insulin dose per patient.

A drastic cut to a patient’s daily insulin dose and improvement to their blood sugar levels are outcomes that Scott Abbott, director of medical development at Valeritas, has come to expect with the company’s device.

“We’ve seen this in almost every study that has been done using the V-Go insulin delivery device,” Abbott told Drug Delivery Business News.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Valeritas Inc.

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS